Prostate Cancer: Clinical Trials

662 trials for Prostate Cancer, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

361 completed, 92 terminated, 80 recruiting, 50 unknown. 662 Phase 1, 250 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 1662Completed 361, Terminated 92, Recruiting 80, Unknown 50, Active not recruiting 42, Withdrawn 18, Not yet recruiting 15, Suspended 3, Enrolling by invitation 1
Phase 2250Completed 115, Terminated 41, Recruiting 39, Unknown 23, Active not recruiting 15, Not yet recruiting 9, Withdrawn 7, Suspended 1

Follow Prostate Cancer: new trials by email Literature Review of Prostate Cancer trials Research Report on Prostate Cancer

Trials (filtered) newest first · largest first

All 662 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study of Personalized PSMA Radiopharmaceutical Therapy
177Lu-PSMA-I&T - escalating renal absorbed dose, 177Lu-PSMA-I&T - recommended phase 2 regime - Cancer, Prostate Cancer
Phase 1 / Phase 2Not yet recruitingCHU de Quebec-Universite Laval5002028-03-012025-03-30
COQ10 and Vitamin E for Off-Target Radiation Toxicity
Coenzyme Q10 Cap/Tab, Vitamin E Cap/Tab - Prostate Cancer, Uterine Cancer
Phase 1 / Phase 2Not yet recruitingUniversity of Nebraska2002026-12-012026-10-08
Testing Pasritamig Before Surgery for the Treatment of Localized Prostate Cancer
Pasritamig - Prostate Cancer
Phase 1Not yet recruitingFred Hutchinson Cancer Center182026-11-302026-10-06
Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer
Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer
Phase 1Not yet recruitingWashington University School of Medicine302026-11-302026-08-10
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
STAR0602, Nivolumab - NSCLC, Non-Small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingNational Cancer Institute (NCI)672026-11-182026-11-13
Docetaxel and SX-682 in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma, Salivary Gland Carcinoma, and Advanced Prostate Cancer
SX-682, DTX - Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma
Phase 1 / Phase 2RecruitingNational Cancer Institute (NCI)1202026-11-182026-11-13
Gene-edited T Regulatory Cells (CRG-150) for the Treatment of Relapsed/Refractory Malignancies
CRG-150 - HR-positive, HER2-negative Breast Cancer, TNBC - Triple-Negative Breast Cancer
Phase 1 / Phase 2Not yet recruitingCoRegen, Inc.672026-11-012026-10-02
Neoadjuvant Intraprostatic OnabotulinumtoxinA Before Radical Prostatectomy for High-Risk Localized Prostate Cancer
OnabotulinumtoxinA (BOTOX®), Normal Saline Placebo - Prostate Cancer
Phase 1 / Phase 2Not yet recruitingThe Methodist Hospital Research Institute302026-11-012026-09-02
A Study of [225Ac]Ac-AKY-2519 in Patients With B7-H3 Expressing Solid Tumors
[225Ac]Ac-AKY-2519 (therapeutic), [64Cu]Cu-AKY-2519 (imaging) - NSCLC, NSCLC (Advanced Non-small Cell Lung Cancer)
Phase 1RecruitingAktis Oncology, Inc.1522026-11-012026-11-02
A Study to Learn How Enzalutamide, Apalutamide and Bicalutamide Affect the Way Fezolinetant is Processed in Men With Prostate Cancer
fezolinetant, enzalutamide, apalutamide - Prostate Cancer
Phase 1RecruitingAstellas Pharma Global Development, Inc.562026-09-252026-10-16
Safety and Preliminary Diagnostic Performance of [⁶⁴Cu]Cu-RAX301 in Prostate Cancer
[⁶⁴Cu]Cu-RAX301 Injection - Prostate Cancer
Phase 1 / Phase 2Not yet recruitingRadAlliance Therapeutics, Inc522026-09-152026-08-14
Phase 1 Trial to Study JANX013 and JANX007 Combination in mCRPC
JANX013, JANX007 - Prostate Cancer, Castration-Resistant Prostate Cancer (CRPC)
Phase 1RecruitingJanux Therapeutics1102026-09-102026-09-17
A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread
BPX-601 - Prostate Cancer
Phase 1RecruitingRegeneron Pharmaceuticals362026-09-082026-09-24
A Multicenter, Open-label Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of SHR-6914 Injection in Participants With Prostate Cancer
SHR-6914 - Prostate Cancer
Phase 1RecruitingSuzhou Suncadia Biopharmaceuticals Co., Ltd.1182026-08-262026-09-08
SL-28 for Advanced Solid Tumours
SL-28 - Head & Neck Cancer, Pancreas Carcinoma
Phase 1 / Phase 2RecruitingSecond Life Therapeutics602026-08-142026-09-15
dMD-002 Pilot Study in Patients With Cavernous Nerve Injury Following Radical Prostatectomy
dMD-002, Control - Prostate Cancer
Phase 1 / Phase 2Not yet recruitingMochida Medical USA, Inc.302026-08-012026-05-15
A Clinical Study of HRS-7525 Tablets in Patients With Advanced Prostate Cancer
HRS-7525 tablets - Prostate Cancer
Phase 1RecruitingJiangsu HengRui Medicine Co., Ltd.3202026-07-302026-09-24
QLF4113 in Participants With Metastatic Prostate Cancer
QLF4113 for injection - Prostate Cancer
Phase 1Not yet recruitingQilu Pharmaceutical Co., Ltd.1402026-07-202026-06-09
Stem Cells for Erectile Dysfunction Post RALP
Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) at the doctor's office, Allogeneic adipose-derived mesenchymal stem cells (HB-adMSCs) in the OR, Placebo in the OR - Erectile Dysfunction, Prostate Cancer
Phase 1 / Phase 2RecruitingThe Methodist Hospital Research Institute402026-07-072026-07-10
A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS
AS1986NS - Prostate Cancer, Prostate Cancer (Adenocarcinoma)
Phase 1 / Phase 2Active not recruitingAntelope Surgical Solutions, Inc152026-07-012026-10-16

Showing 20 of 662. Sign in to see all of them.

Narrower conditions

Prostatic Neoplasms (662)  ·  Breast Neoplasms (97)  ·  Ovarian Neoplasms (65)  ·  Neoplasms (60)  ·  Carcinoma, Non-Small-Cell Lung (54)  ·  Pancreatic Neoplasms (44)  ·  Colorectal Neoplasms (43)  ·  Neoplasm Metastasis (43)  ·  Lung Neoplasms (42)  ·  Urinary Bladder Neoplasms (34)  ·  Head and Neck Neoplasms (32)  ·  Stomach Neoplasms (30)  ·  Melanoma (29)  ·  Esophageal Neoplasms (27)  ·  Colonic Neoplasms (24)

Broader conditions

Urogenital Diseases (662)  ·  Genital Diseases (661)  ·  Male Urogenital Diseases (660)  ·  Genital Diseases, Male (658)  ·  Neoplasms by Site (658)  ·  Genital Neoplasms, Male (657)  ·  Urogenital Neoplasms (655)  ·  Prostatic Diseases (654)  ·  Neoplasms (602)  ·  Skin and Connective Tissue Diseases (118)  ·  Skin Diseases (117)  ·  Breast Diseases (109)  ·  Female Urogenital Diseases (104)  ·  Female Urogenital Diseases and Pregnancy Complications (104)  ·  Neoplasms by Histologic Type (97)

Interventions

Docetaxel (47)  ·  Prednisone (32)  ·  enzalutamide (22)  ·  Abiraterone Acetate (17)  ·  Radiotherapy (16)  ·  bicalutamide (16)  ·  Leuprolide (15)  ·  pembrolizumab (14)  ·  Goserelin (12)  ·  Estramustine (11)  ·  Paclitaxel (11)  ·  Cyclophosphamide (10)  ·  Radiotherapy, Intensity-Modulated (10)  ·  abiraterone (10)  ·  gallium 68 PSMA-11 (10)

Sponsors

Memorial Sloan Kettering Cancer Center (40)  ·  National Cancer Institute (NCI) (20)  ·  M.D. Anderson Cancer Center (14)  ·  Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (14)  ·  Weill Medical College of Cornell University (12)  ·  AstraZeneca (9)  ·  Jiangsu HengRui Medicine Co., Ltd. (8)  ·  Dana-Farber Cancer Institute (7)  ·  NYU Langone Health (7)  ·  Amgen (6)  ·  Cell Genesys (6)  ·  Jonsson Comprehensive Cancer Center (6)  ·  Molecular Insight Pharmaceuticals, Inc. (6)  ·  University of California, San Francisco (6)  ·  University of Chicago (6)

Countries

United States (462)  ·  China (49)  ·  United Kingdom (40)  ·  Australia (36)  ·  Canada (33)  ·  France (20)  ·  Spain (19)  ·  Germany (15)  ·  Japan (14)  ·  Netherlands (13)  ·  South Korea (12)  ·  Belgium (9)  ·  Italy (9)  ·  Norway (7)  ·  Denmark (6)

Top investigators

Rahul Aggarwal, MD (7)  ·  Susan Slovin, MD, PhD (7)  ·  Michael Morris, MD (6)  ·  Scott Tagawa, MD (5)  ·  Arie Belldegrun, MD, FACS (3)  ·  Dana Rathkopf, MD (3)  ·  Howard I. Scher, MD (3)

Results publications

PMID 33465252, PMID 36383907, PMID 22747660, PMID 25475068, PMID 25974235, PMID 39853781, PMID 10661346, PMID 11828001, PMID 12694838, PMID 14504052, PMID 14529764, PMID 14967428, PMID 15590164, PMID 15671557, PMID 15735119, PMID 15936549, PMID 16145049, PMID 17920349, PMID 18245546, PMID 18384719, PMID 19375217, PMID 19499186, PMID 19577865, PMID 19706807, PMID 20398925, PMID 20407240, PMID 20501622, PMID 20598811, PMID 20818327, PMID 20824184, PMID 21163871, PMID 21377288, PMID 21414514, PMID 21917625, PMID 22213823, PMID 22280805, PMID 22326922, PMID 22342302, PMID 22343504, PMID 22633552, PMID 22673726, PMID 22847809, PMID 23320927, PMID 23487599, PMID 23522299, PMID 23535954, PMID 23609828, PMID 23624851, PMID 23653243, PMID 23790772

NIH funding

2014 (5), 2017 (4), P30CA008748 (4), 2019 (3), 2023 (3), P30CA015083 (3), 2009 (2), 2025 (2), P30CA033572 (2), P30CA072720 (2), P50CA058204 (2), U01CA069912 (2), 2015 (1), 2018 (1), K01HL161419 (1)